On Sept. 8, 2022, the Fred Hutchinson Cancer Center (FHCRC) announced that Stuart and Molly Sloan had pledged $78 million, the largest in Fred Hutch history, to help fund a new research building on the Seattle campus. The gift will further advance Fred Hutch’s work in precision oncology, which integrates fundamental biology, technology, immunology, data science and clinical experience into strategies to prevent, detect and treat cancer.

Precision oncology aims to stop cancer by examining its biological make up in each person. In the past decade, potential targets for cancer therapies and the technical tools to study them have both expanded greatly, along with advances in prevention and detection methods.